Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.8
(-1.36%)
EUR 5.8
(-1.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -15.38 Million EUR | -42.8% |
| 2022 | -10.77 Million EUR | 6.99% |
| 2021 | -11.57 Million EUR | -62.03% |
| 2020 | -7.14 Million EUR | -23.89% |
| 2019 | -5.76 Million EUR | 0.4% |
| 2018 | -5.79 Million EUR | -55.8% |
| 2017 | -3.71 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q2 | -3.31 Million EUR | 0.0% |
| 2023 Q3 | -4.37 Million EUR | -31.84% |
| 2023 Q1 | -3.31 Million EUR | 4.74% |
| 2023 FY | -15.38 Million EUR | -42.8% |
| 2023 Q4 | -4.37 Million EUR | 0.0% |
| 2022 Q2 | -4.94 Million EUR | -100.0% |
| 2022 FY | -10.77 Million EUR | 6.99% |
| 2022 Q4 | -3.48 Million EUR | 0.0% |
| 2022 Q3 | -3.48 Million EUR | 29.54% |
| 2022 Q1 | -2.47 Million EUR | 26.0% |
| 2021 FY | -11.57 Million EUR | -62.03% |
| 2021 Q4 | -3.33 Million EUR | -100.0% |
| 2021 Q3 | -1.66 Million EUR | 79.74% |
| 2021 Q2 | -8.24 Million EUR | -100.0% |
| 2021 Q1 | -4.12 Million EUR | -142.14% |
| 2020 Q2 | -2.63 Million EUR | -66.96% |
| 2020 FY | -7.14 Million EUR | -23.89% |
| 2020 Q4 | -1.7 Million EUR | 0.0% |
| 2020 Q1 | -1.58 Million EUR | 26.43% |
| 2020 Q3 | -1.7 Million EUR | 35.5% |
| 2019 Q2 | -580 Thousand EUR | 16.06% |
| 2019 Q3 | -2.14 Million EUR | -270.26% |
| 2019 Q1 | -691 Thousand EUR | 0.0% |
| 2019 FY | -5.76 Million EUR | 0.4% |
| 2019 Q4 | -2.14 Million EUR | 0.0% |
| 2018 FY | -5.79 Million EUR | -55.8% |
| 2017 FY | -3.71 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -337.18% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 89.59% |
| Adocia SA | -21.16 Million EUR | 27.323% |
| Aelis Farma SA | -5.07 Million EUR | -202.875% |
| Biophytis S.A. | -17.02 Million EUR | 9.668% |
| Advicenne S.A. | -7.03 Million EUR | -118.746% |
| genOway Société anonyme | 1.56 Million EUR | 1081.133% |
| IntegraGen SA | -171.39 Thousand EUR | -8873.215% |
| Medesis Pharma S.A. | -3.95 Million EUR | -288.434% |
| Neovacs S.A. | -8.74 Million EUR | -75.903% |
| NFL Biosciences SA | -3.74 Million EUR | -310.629% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 19526.796% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -385.029% |
| Sensorion SA | -22.06 Million EUR | 30.292% |
| Theranexus Société Anonyme | -6.82 Million EUR | -125.251% |
| TME Pharma N.V. | -6.73 Million EUR | -128.325% |
| Valbiotis SA | -7.36 Million EUR | -108.74% |
| TheraVet SA | -1.57 Million EUR | -879.177% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 24.4% |
| argenx SE | -272.91 Million EUR | 94.365% |
| BioSenic S.A. | -28.77 Million EUR | 46.556% |
| Celyad Oncology SA | -8.44 Million EUR | -82.055% |
| DBV Technologies S.A. | -67.26 Million EUR | 77.137% |
| Galapagos NV | 211.69 Million EUR | 107.265% |
| Genfit S.A. | -28.89 Million EUR | 46.771% |
| GeNeuro SA | -14.75 Million EUR | -4.222% |
| Innate Pharma S.A. | -7.57 Million EUR | -103.17% |
| Inventiva S.A. | -110.42 Million EUR | 86.072% |
| MaaT Pharma SA | -19.71 Million EUR | 21.996% |
| MedinCell S.A. | -25.03 Million EUR | 38.573% |
| Nanobiotix S.A. | -39.7 Million EUR | 61.259% |
| Onward Medical N.V. | -36.18 Million EUR | 57.492% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -358.702% |
| OSE Immunotherapeutics SA | -23 Million EUR | 33.139% |
| Oxurion NV | -18.96 Million EUR | 18.92% |
| Pharming Group N.V. | -9.75 Million EUR | -57.637% |
| Poxel S.A. | -35.09 Million EUR | 56.17% |
| GenSight Biologics S.A. | -26.22 Million EUR | 41.342% |
| Transgene SA | -22.32 Million EUR | 31.118% |
| Financière de Tubize SA | 88.15 Million EUR | 117.447% |
| UCB SA | 343 Million EUR | 104.484% |
| Valneva SE | -101.42 Million EUR | 84.837% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 45.734% |